6-bromomethyl-7-(2,2-dimethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile | 501125-49-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: 6-bromomethyl-7-(2,2-dimethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
• 英文别名: 6-(bromomethyl)-7-(2,2-dimethylpropyl)pyrrolo[2,3-d]pyrimidine-2-carbonitrile
• CAS: 501125-49-1
• 化学式: C₁₃H₁₅BrN₄
• 分子量: 307.193
• InChiKey: SVNIABUZGXNWNA-UHFFFAOYSA-N

物化性质

• 沸点：
  454.7±53.0 °C(Predicted)
• 密度：
  1.41±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  54.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-bromomethyl-7-(2,2-dimethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile 在 sodium hydride 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 4.5h， 以68%的产率得到1-[2-cyano-7-(2,2-dimethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidin-6-ylmethyl]-5-methoxy-2-oxo-1,2-dihydro-1'H-spiro[indole-3,4'-piperidine]-1'carboxylic acid tert-butyl ester
  参考文献：
  名称：

  [EN] SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES
  [FR] PYRROLOPYRIMIDINES SPIRO-SUBSTITUEES

  摘要：

  该发明提供了式（I）的化合物或其药用可接受的盐或酯的公式（I），其中符号的含义如描述中所定义。所述化合物是猫hepsin K和/或猫hepsin S的抑制剂，并且对于治疗猫hepsin K和/或猫hepsin S参与的疾病和医疗状况是有用的，例如各种疾病，包括神经病痛、炎症、类风湿性关节炎、骨关节炎、骨质疏松症、多发性硬化和肿瘤。

  公开号：

  WO2004076455A1
• 作为产物：
  描述：

  7-(2,2-dimethyl-propyl)-6-hydroxymethyl-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile 在 四溴化碳 、 三苯基膦 作用下， 以 二氯甲烷 为溶剂， 反应 3.5h， 以78%的产率得到6-bromomethyl-7-(2,2-dimethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
  参考文献：
  名称：

  Novel scaffold for cathepsin K inhibitors

  摘要：

  Pyrrolopyrimidine, a novel scaffold, allows to adjust interactions within the S3 subsite of cathepsin K. The core intermediate 10 facilitated the P3 optimization and identified highly potent and selective cathepsin K inhibitors 11-20.

  DOI：

  10.1016/j.bmcl.2007.09.047

文献信息

• Pyrrolo pyrimidines as agents for the inhibition of cystein proteases
  申请人：Betschart Claudia

  公开号：US20050054851A1

  公开（公告）日：2005-03-10

  The invention provides compounds of Formula I or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors.

  本发明提供了I式化合物或其药学上可接受的盐或酯，其中符号的含义如定义所述，它们是猫hepsin K的抑制剂，并在药学上用于治疗猫hepsin K参与的疾病和医疗情况，例如各种疾病，包括炎症、类风湿性关节炎、骨关节炎、骨质疏松和肿瘤。
• Spiro-substituted pyrrologyrimidines
  申请人：Irie Osamu

  公开号：US20060258690A1

  公开（公告）日：2006-11-16

  The invention provides compounds of formula (I) or a pharmaceutically acceptable salt or ester thereof formula (I) wherein the symbols have the meaning as defined in the description. Said compounds are inhibitors of cathepsin K and/or cathepsin S and are useful for the treatment of diseases and medical conditions in which cathepsin K and/or cathepsin S is implicated, e.g. various disorders including neuropathic pain, inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, multiple sclerosis and tumours.

  本发明提供了公式（I）的化合物，或其药学上可接受的盐或酯，其中符号的含义如描述中所定义。所述化合物是猫hepsin K和/或猫hepsin S的抑制剂，可用于治疗与猫hepsin K和/或猫hepsin S有关的疾病和医学情况，例如各种紊乱，包括神经病理性疼痛、炎症、类风湿性关节炎、骨关节炎、骨质疏松症、多发性硬化和肿瘤。
• Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases
  申请人：Betschart Claudia

  公开号：US20090054467A1

  公开（公告）日：2009-02-26

  The invention provides compounds of Formula I or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors.

  本发明提供了公式I的化合物，或其药理学上可接受的盐或酯，其中符号具有定义的含义，这些化合物是卡特普西林K的抑制剂，并在药学上用于治疗与卡特普西林K有关的疾病和医疗条件，例如各种疾病，包括炎症，类风湿性关节炎，骨关节炎，骨质疏松和肿瘤。
• Spiro-substituted pyrrolo[2,3-D]pyrimidines as cathepsin inhibitors
  申请人：Novartis AG

  公开号：US07531546B2

  公开（公告）日：2009-05-12

  The invention provides compounds of formula (I) or a pharmaceutically acceptable salt or ester thereof formula (I) wherein the symbols have the meaning as defined in the description. Said compounds are inhibitors of cathepsin K and/or cathepsin S and are useful for the treatment of diseases and medical conditions in which cathepsin K and/or cathepsin S is implicated, e.g. various disorders including neuropathic pain, inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, multiple sclerosis and tumors.

  本发明提供了公式(I)的化合物或其药学上可接受的盐或酯，其中符号的含义如描述中所定义。所述化合物是猫hepsin K和/或猫hepsin S的抑制剂，可用于治疗与猫hepsin K和/或猫hepsin S有关的疾病和医学状况，例如各种疾病，包括神经病理性疼痛，炎症，类风湿性关节炎，骨关节炎，骨质疏松症，多发性硬化和肿瘤。
• SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES
  申请人：Irie Osamu

  公开号：US20090186889A1

  公开（公告）日：2009-07-23

  The invention provides compounds of formula I or a pharmaceutically acceptable salt or ester thereof formula I wherein the symbols have the meaning as defined in the description. Said compounds are inhibitors of cathepsin K and/or cathepsin S and are useful for the treatment of diseases and medical conditions in which cathepsin K and or cathepsin S is implicated, e.g. various disorders including neuropathic pain, inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, multiple sclerosis and tumours.

  该发明提供了I式化合物或其药学上可接受的盐或酯，其中符号的含义如描述中所定义。所述化合物是cathepsin K和/或cathepsin S的抑制剂，可用于治疗与cathepsin K和/或cathepsin S有关的疾病和医疗条件，例如各种紊乱，包括神经病性疼痛、炎症、类风湿性关节炎、骨关节炎、骨质疏松症、多发性硬化症和肿瘤。